APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 1.5mg capsule bottle

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

rivastigmine hydrogen tartrate, Quantity: 2.4 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

rivastigmine hydrogen tartrate

Forma farmaceutica:

Capsule

Composizione:

Excipient Ingredients: titanium dioxide; stearic acid; iron oxide yellow; maize starch; Gelatin; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Via di somministrazione:

Oral

Confezione:

100, 56, 500

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Dettagli prodotto:

Visual Identification: Hard gelatine calsule with yellow, opaque body and yellow opaque cap. Imprinted "APO R1.5" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2010-07-27